| 000 | 01879cam a2200325 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 008 | 140121s2013 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.11.32.Ph.D.2013.Me.S | ||
| 100 | 0 | _aMervat Mahmoud Mostafa Eissa | |
| 245 | 1 | 0 |
_aSerum selerostin level among Egyptian rheumatoid arthritis patients : _bRelation to bone mineral density, disease activity and radiological grading / _cMervat Mahmoud Mostafa Eissa ; Supervised Somaya Anwar Hussein , Sahar Fakhr Eldin Mohamed , Dina Ahmed Mehaney |
| 246 | 1 | 5 | _aدراسة عن مستوى السكليروستين بمرضى الروماتويد المصريين و علاقته بكثافة العظام و نشاط المرض و الأشعة |
| 260 |
_aCairo : _bMervat Mahmoud Mostafa Eissa , _c2013 |
||
| 300 |
_a236 P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Rheumatology and Rehabilitation | ||
| 520 | _aBone loss in rheumatoid arthritis (RA) is caused by increased bone resorption, however, there is no increased bone formation. The Wnt pathway is important in the control of bone formation through regulation of osteoblast activity. Selerostin is an important regulator of regulation of osteoblast activity. Selerostin is an important regulator of the Wnt pathway by blocking Wnt binding to its receptor and therapy inhibiting bone formation | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aBone mineral density | |
| 653 | 4 | _aRheumatoid arthritis | |
| 653 | 4 | _aSelerostin | |
| 700 | 0 |
_aDina Ahmed Mehaney , _eSupervisor |
|
| 700 | 0 |
_aSahar Fakhr Eldin Mohamed , _eSupervisor |
|
| 700 | 0 |
_aSomaya Anwar Hussein , _eSupervisor |
|
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSamia _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c44928 _d44928 |
||